BiotechTube
Home/Arovella/Dr Andrew Nash
DA

Dr Andrew Nash

Non‑Executive Director

Arovella

Therapeutic Areas

Oncology

Arovella Pipeline

DrugIndicationPhase
ALA-101CD19+ B‑cell lymphomas and leukaemiasPreclinical
ALA-105Claudin‑18.2+ gastric, gastro‑oesophageal junction, and pancreatic cancersPreclinical

Leadership Team at Arovella

DM
Dr Michael Baker
CEO & Managing Director
DN
Dr Nicole van der Weerden
Chief Operating Officer
LM
Lachie Mallia
Chief Financial Officer
DD
Dr Deborah Barton
Non‑Executive Director
DR
Dr Robson Dossa
Senior VP Manufacturing & Quality
DM
Dr Michelle Ferguson
Senior Director Research & Development
JC
Jacqui Cumming
Senior Director Clinical Development
View full Arovella profile